Ultragenyx Pharmaceutical (NASDAQ:RARE) Announces Quarterly Earnings Results, Misses Estimates By $0.31 EPS

Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($2.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.72) by ($0.31), Briefing.com reports. Ultragenyx Pharmaceutical had a negative net margin of 138.58% and a negative return on equity of 421.88%. The business had […]

Related Keywords

United States ,Japan ,America ,Robertw Baird ,Karah Herdman Parschauer ,Matthewk Fust ,Canaccord Genuity Group ,Ultragenyx Pharmaceutical Inc ,Securities Exchange Commission ,Cantor Fitzgerald ,Ultragenyx Pharmaceutical ,Get Free Report ,Genuity Group ,Herdman Parschauer ,Exchange Commission ,Director Matthew ,Pharmaceutical Inc ,North America ,Latin America ,Ultragenyx Pharmaceutical Daily ,Nasdaq Rare ,Rare ,Medical ,Earnings ,